Ultime notizie per Edesa Biotech (NASDAQ:EDSA) Azioni

Edesa Biotech

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Edesa Biotech Inc

Earnings

News

Guidance

AngloGold Ashanti Q3 Adjusted EBITDA $746M, Up 339% Y/Y; Reaffirms Full-year Guidance For Gold Production, Costs And Capital Expenditure

By utilizing the cloud-native and modular capabilities of DeepHealth OS, ONRAD will implement a customized solutions roadmap targeted to streamline its clinical and operational workflows, enhancing productivity, and ultimately improving patient outcomes through AI-powered, unified data integration.

Health Care

Contracts

General

RDNT

RadNet Announced That ONRAD Has Selected RadNet's DeepHealth OS To Advance Its Next Generation Of Radiology Services

Haemonetics Reiterated FY25 Adjusted Earnings Per Diluted Share Outlook Of $4.45-$4.75 Vs. $4.59 Estimate

Haemonetics Projects Total Company FY25 Reported Revenue Growth Of 5%-8% (Reiterated); Sees Organic Revenue Growth Of 1%-4% (Prior View: 0-3%)

Ducommun (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.74 by 33.78 percent. The company reported quarterly sales of $201.41 million which beat the analyst consensus estimate of $194.10 million by 3.76 percent. This is a 2.63 percent increase over sales of $196.25 million the same period last year.

Ducommun Q3 2024 Adj EPS $0.99 Beats $0.74 Estimate, Sales $201.41M Beat $194.10M Estimate

Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>), the world's leading lithium producer, reported a challenging third quarter, revealing a net loss of $1.1b amidst a continued downturn in <a target="_blank" href="https://www.benzinga.com/topic/lithium" rel="noreferrer noopener">lithium prices</a>.
Despite a market slump, fueled by a supply surplus from China and a demand-dampening slower EV adoption – Albemarle saw a 16% rise in lithium sales volume year-over-year.
Management expects the downturn to endure, so it has announced measures to adjust to these market conditions: streamlining business units and announcing workforce reductions of 6-7% globally, primarily impacting non-manufacturing roles.
"Through our strategic review of Albemarle's cost and operating structure, we have identified significant opportunities to reduce costs, improve productivity, and decrease capital spending," <a target="_blank" href="https://www.albemarle.com/global/en/news/albemarle-reports-third-quarter-2024-results" rel="noreferrer noopener">stated</a> CEO Kent Masters. These efforts are projected to save the company $300 to $400 million annually.
Albemarle also plans to reduce capital expenditures significantly in 2025, setting a range of $800 million to $900 million to sustain its current assets. This budget cut aligns with the company's expectation that lithium prices may remain between $12 and $15 per kilogram for the foreseeable future.
Despite these challenges, Albemarle maintained its full-year outlook, citing improved productivity, higher lithium volumes, and long-term supply contracts, which helped offset the impact of declining market prices.
Looking forward, Albemarle and its peers remain hopeful that demand for lithium will surge later in the decade, particularly as North American EV sales hit record highs in the third quarter of 2024. The company expects EV prices to achieve parity with combustion-engine vehicles by 2025, supporting long-term growth in lithium demand.
The recent U.S. election has focused additional attention on the industry, as Donald Trump's return to office could favor domestic lithium production.
"A strong America cannot be dependent on imports from foreign adversaries for the critical minerals necessary to maintain our economic and military strength," Trump declared in a 2020 executive order.
Notably, Trump's final act before leaving office in 2021 was to green-light the Thacker Pass lithium mine, the largest known sedimentary lithium deposit.
His protectionist stance and close ties with Tesla CEO Elon Musk suggest that his policies may benefit domestic lithium producers.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41769288/donald-trumps-victory-could-disrupt-commodities-put-australia-in-precarious-position" target="_blank" rel="noreferrer noopener">Donald Trump's Victory Could Disrupt Commodities, Put Australia In Precarious Position</a></li>
</ul>
Photo via Shutterstock

Commodities

Albemarle Adjusts To Lower-For-Longer Lithium Prices, Cuts Capex, Announces Layoffs

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">Fourth Quarter &amp; Full Year 2024 Financial Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="3">For the Fourth Quarter and Full Year 2024, the Company currently expects (dollars in millions):</td>
</tr>
<tr>
<td>Q4 2024</td>
<td rowspan="2">​</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">Unaudited</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">(dollars in millions)</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenues</td>
<td>$460 - $490</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$180 - $196</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>ex-TAC Gross Profit&#x2A;</td>
<td>$205 - $221</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Adjusted EBITDA&#x2A;</td>
<td>$83 - $99</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Non-GAAP Net Income (Loss)&#x2A;</td>
<td>$37 - $53</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

TBLA

Taboola.com Expects Q4 Revenue Of $460M-$490M Vs $480.12M Est, Reiterated FY24 Revenue Of $1.735B-$1.765B Vs $1.75B Est

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $12 price target.

Price Target

Reiteration

Analyst Ratings

CHRS

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Canadian Tire Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CDNAF#OTC">CDNAF</a>) reported quarterly earnings of $2.63 per share. This is a 19 percent increase over earnings of $2.21 per share from the same period last year. The company reported $3.07 billion in sales this quarter. This is a 2.97 percent decrease over sales of $3.17 billion the same period last year.

CDNAF

Canadian Tire Corp Q3 Adj $2.63 Up From $2.21 YoY, Sales $3.07B Down From $3.17B YoY

RAISING 2024 GUIDANCE
For the full year of 2024, we are raising our guidance for both revenue and adjusted EBITDA. We now expect revenue to be in the range of $1.567 billion to $1.601 billion, up from the range of $1.557 billion to $1.591 billion. We now expect adjusted EBITDA to be in the range of $433 million to $448 million, up from the range of $423 million to $438 million.

ACIW

ACI Worldwide Raises 2024 Guidance: Now Expects Revenue Of $1.567B-$1.601B (Prior $1.557B-$1.591B Vs $1.577B Est.; Sees Adj. EBITDA Of $433M-$448M (Prior $423M-$438M)

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) with a Buy and maintains $18 price target.

ARQT

Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $18 Price Target

Manitex International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTX#NASDAQ">MNTX</a>) reported quarterly earnings of $0.09 per share. This is a 35.71 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $66.54 million which missed the analyst consensus estimate of $70.00 million by 4.94 percent. This is a 6.71 percent decrease over sales of $71.33 million the same period last year.

MNTX

Manitex International Q3 2024 Adjusted EPS $0.09 Down From $0.14 YoY, Sales $66.54M Miss $70.00M Estimate

Buybacks

Cenovus Energy Approves Renewal Of Normal Course Issuer Bid To Purchase Up To 127.49M Common Shares During 12-month Period Commencing November 11, 2024 And Ending November 10, 2025.

Geo Group Sees Q4 EPS Of $0.19-$0.22 Vs. $0.27 Estimate, Projects Revenues Of $600M-$610M Vs. $618.58M Estimate

On Wednesday, November 6th, U.S. markets closed at record highs as Donald Trump won the 2024 presidential election. Investors anticipated lower taxes, deregulation, and Trump&#8217;s active stance on economic matters. The Dow, S&amp;P 500, and Nasdaq surged, while bitcoin also reached new highs.
Tesla shares surged, fueled by CEO Elon Musk&#8217;s endorsement of Trump, alongside gains in Trump Media &amp; Technology Group. Treasury yields rose amid expectations that higher tariffs could drive up inflation and expand the U.S. deficit.
According to economic data, U.S. mortgage applications dropped 10.8% last week, while crude oil inventories rose by 2.149 million barrels, exceeding the forecast of 1.8 million.
Most S&amp;P 500 sectors closed higher, led by consumer discretionary, industrials, and financials, while consumer staples and real estate lagged.
The Dow Jones Industrial Average gained 3,57% to close at 43,729.93, the S&amp;P 500 rose 2.53% to 5,929.04, and the Nasdaq Composite soared 2.95% to finish at 18,983.47.
Asia Markets Today
<ul>
<li>On Thursday, Japan&#8217;s Nikkei 225 declined 0.09% and ended the session at 39,394.00, led by losses in the Fishery, Marine Transport, and Food sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.33% and ended the day at 8,226.30, led by gains in the Energy, Industrials and Financials sectors.</li>
<li>India&#8217;s Nifty 50 traded lower by 1.18% at 24,194.60 and Nifty 500 was down 1.02% at 22,796.95, losses in the Metals, Power and Real Estate sectors.</li>
<li>China&#8217;s Shanghai Composite gained 2.57% to close at 3,470.66, and the Shenzhen CSI 300 soared 3.02%, finishing the day at 4,145.70.</li>
<li>Hong Kong&#8217;s Hang Seng rose 2.02% and closed the session at 20,953.34.</li>
</ul>
Eurozone at 05.45 AM ET
<ul>
<li>The European STOXX 50 index was up 0.67%.</li>
<li>Germany&#8217;s DAX gained 1.27%.</li>
<li>France&#8217;s CAC rose 0.58%.</li>
<li>U.K.&#8217;s FTSE 100 traded higher by 0.08%.</li>
</ul>
Commodities at 05.45 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.88% at $71.06/bbl, and Brent was down 0.71% at $74.41/bbl.</li>
<li>Natural Gas slid 0.07% to $2.745</li>
<li>Gold was trading lower by 0.08% at $2,674.70, Silver fell 0.29% to $31.245, and Copper gained 2.28% to $4.3430.</li>
</ul>
U.S. Futures at 05.45 AM ET
Dow futures climbed 0.22%, with S&amp;P 500 futures up 0.19% and Nasdaq 100 futures rising 0.21%.
Forex at 05.45 AM ET
<ul>
<li>The U.S. dollar index declined 0.19% to 104.89, the USD/JPY was down 0.40% to 154.00, and the USD/AUD fell 0.89% to 1.5086.</li>
<li>Global stocks rose, led by optimism over potential U.S. fiscal expansion under Trump&#8217;s presidency and anticipated rate cuts from the Fed and other central banks. U.S. Treasury yields increased, while the dollar eased slightly after Wednesday&#8217;s surge.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Forex

Markets

ADIV

AGOV

ASHR

BBEU

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

US Futures, European Stocks Rally Post-Trump Victory While Crude Oil And Gold Decline - Global Markets Today While US Slept

Fourth Quarter and Full Year 2024 Guidance&nbsp;
We expect fourth quarter 2024 revenue of $202-$204 million and Total Bookings of $224-$226 million.&nbsp;
For the full year of 2024, we expect to deliver expanding margins and Free Cash Flow growth of at least 40% versus 2023.

Clear Secure Expects Q4 Revenue Of $202M-$204M Vs. $200.35M Est; Bookings Of $224M-$226M

Under the FEED contract, KBR will provide engineering services for the complex's fourth LNG train, which will have a capacity of 3.8 million tons per annum. The project will involve the addition or expansion of utilities, an LNG tank, the jetty, and associated infrastructure.

KBR Has Been Awarded A Front-end Engineering Design Contract For The Expansion Of The Qalhat LNG Complex In Sur, Oman

Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) raises FY2024 sales outlook from $1.64 billion-1.68 billion to $1.68 billion.

PRVA

Privia Health Gr expects FY24 revenue at high end of prior guidance range of $1.600-$1.675B vs. est. $1.83B.

HC Wainwright &amp; Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) with a Buy and maintains $16 price target.

SLDB

HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target

Townsquare Expects Q4 Net Revenue Of $114.8 Million And $118.8 Million (Est $121.299M), Narrows FY24 Outlook From $440M - $455M To $448M - $452M, Est $454.302M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Edesa Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/edsa-stock-quote/">EDSA</a>) just reported results for the second quarter of 2024.<ul><li>Edesa Biotech reported earnings per share of -58 cents. This was above the analyst estimate for EPS of -69 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/edsa-stock-earnings-edesa-biotech-for-q2-of-2024/">EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024

An update from Edesa Biotech (EDSA) is now available. Edesa Biotech, Inc. shareholders have given the green light to a key amendment that boosts th...

Edesa Biotech Shareholders Approve Board and Compensation Plans

Edesa Biotech (EDSA) has released an update. Edesa Biotech's novel drug, paridiprubart, has been selected by the U.S. Biomedical Advanced Research ...

Edesa Biotech's ARDS Drug Chosen for US Trial

Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Edesa Biotech (EDSA – Research Report). The associated price targe...

Promising Outlook for Edesa Biotech's Paridiprubart: A Buy Rating Justified by BARDA-Backed ARDS Study and Broad Therapeutic Potential

Edesa Biotech GAAP EPS of -$0.52 beats by $0.06

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its third-quarter financials ...

Edesa Biotech Showcases Steady Q3 2024 Financials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Edesa Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/edsa-stock-quote/">EDSA</a>) just reported results for the third quarter of 2024.<ul><li>Edesa Biotech reported earnings per share of -52 cents. This was above the analyst estimate for EPS of -58 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/edsa-stock-earnings-edesa-biotech-for-q3-of-2024/">EDSA Stock Earnings: Edesa Biotech Beats EPS for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EDSA Stock Earnings: Edesa Biotech Beats EPS for Q3 2024

Buy Rating Affirmed for Edesa Biotech Amidst Strong Government Support and Promising Drug Pipeline

Edesa Biotech ( ($EDSA) ) has issued an update. Edesa Biotech, Inc. has partnered with H.C. Wainwright & Co., LLC to periodically sell its common s...

Edesa Biotech Partners with Wainwright for Share Sales

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, is set to participate in multiple internati...

Comments

Edesa Biotech

Notizie

Ultime notizie per Edesa Biotech (NASDAQ:EDSA) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO